This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Over 18 years old.
Advanced-stage malignant solid tumor managed in a non-curative context.
Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
Patient able to read, write, and understand the French language.
Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.
Severe or uncontrolled systemic disease.
Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.
Pregnant women, women in labor, and breastfeeding mothers,
Single group
Blood sample taken for the liquid biopsy
Procedure/Surgery36 mL will be taken for the study.
Sensitivity of liquid biopsy versus solid biopsy (gold standard)
The primary endpoind is the sensitivity of liquid biopsy versus solid biopsy as the gold standard for detecting genomic alterations evaluated in the studied gene panel. The panel will consist of 70 genes common to the PanoraMix panels (125 genes, FFPE) and Avida (104 genes, cpDNA).
Specificity of liquid biopsy versus solid biopsy (gold standard)
The specificity of liquid biopsy versus solid biopsy as the gold standard in the detection of genomic alterations evaluated in the studied gene panel.
Failure rate of molecular screening
The failure rate of molecular screening (defined as the inability to provide the genetic profile from the liquid biopsy due to technical failure).
Clinical factors predictive of the sensitivity of liquid biopsy.
Clinical factors predictive of the sensitivity of liquid biopsy.
Rate of unexploitable results
The rate of unexploitable results, defined as the rate of results that do not allow for classification for each technique of the results as True Positive, False Positive, False Negative, or True Negative.
Click on the lead sponsor to view all of their trials.
